Literature DB >> 18210153

Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis.

Teresa A Zimmers1, Xiaoling Jin, Juan C Gutierrez, Cary Acosta, Iain H McKillop, Robert H Pierce, Leonidas G Koniaris.   

Abstract

BACKGROUND: Growth/differentiation factor-15(GDF-15) is a divergent TGF-beta family member that is expressed following liver injury and carcinogen exposure. GDF-15 expression is highly associated with gastrointestinal cancer stage, size, and metastasis and has been implicated in inhibition of tumor growth and increased tumor invasiveness. The current study sought to determine the effect of GDF-15 ablation on the development of hepatocellular carcinoma (HCC) in vivo.
MATERIALS AND METHODS: Male mice genetically deleted for the gene encoding GDF-15 (Gdf15 (-/-) mice) and wild-type controls were exposed to the hepatocarcinogen diethylnitrosamine (DEN). Mice were killed at 6 months of age and their livers dissected and processed for histology. Tumor number and size relative to total liver area examined were determined.
RESULTS: At 6 months of age, tumors were identified in 16 of 20 (80%) Gdf15 (-/-) mice and 16 of 19 wild-type mice (84%). No significant difference in tumor-occupied area was observed in Gdf15 (-/-) mice versus wild-type mice. In addition, no difference in invasiveness was observed in HCC arising in Gdf15 (-/-) as compared to wild-type mice. In wild type mice strong immunohistochemical staining for GDF-15 was noted on small HCC foci, whereas a loss of GDF-15 expression was found in a number of advanced HCC tumors.
CONCLUSIONS: Although highly expressed in association with multiple gastrointestinal cancers, and lost in some advanced HCC, genetic ablation of GDF-15 has no apparent effect on HCC tumor formation rate, growth rate or invasiveness in diethylnitrosamine-induced HCC in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18210153     DOI: 10.1007/s00432-007-0336-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Profile of gene expression regulated by induced p53: connection to the TGF-beta family.

Authors:  K Kannan; N Amariglio; G Rechavi; D Givol
Journal:  FEBS Lett       Date:  2000-03-17       Impact factor: 4.124

2.  Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms.

Authors:  Teresa A Zimmers; Xiaoling Jin; Edward C Hsiao; Eduardo A Perez; Robert H Pierce; Kenneth D Chavin; Leonidas G Koniaris
Journal:  J Surg Res       Date:  2005-09-12       Impact factor: 2.192

3.  Transient down-regulation of inhibin-betaC expression following partial hepatectomy.

Authors:  A F Esquela; T A Zimmers; L G Koniaris; J V Sitzmann; S J Lee
Journal:  Biochem Biophys Res Commun       Date:  1997-06-27       Impact factor: 3.575

4.  Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms.

Authors:  K L Weber; M E Bolander; M G Rock; D Pritchard; G Sarkar
Journal:  J Orthop Res       Date:  1998-01       Impact factor: 3.494

5.  Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.

Authors:  P X Li; J Wong; A Ayed; D Ngo; A M Brade; C Arrowsmith; R C Austin; H J Klamut
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

6.  Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration.

Authors:  L G Koniaris; T Zimmers-Koniaris; E C Hsiao; K Chavin; J V Sitzmann; J M Farber
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

7.  Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha.

Authors:  M E Vail; R H Pierce; N Fausto
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

8.  Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids.

Authors:  Donna Newman; Morito Sakaue; Ja Seok Koo; Kyung-Su Kim; Seung Joon Baek; Thomas Eling; Anton M Jetten
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

Review 9.  From TGF-beta to cancer therapy.

Authors:  Xuemei Huang; Chung Lee
Journal:  Curr Drug Targets       Date:  2003-04       Impact factor: 3.465

10.  Induction of MIC-1/growth differentiation factor-15 following bile duct injury.

Authors:  Leonidas G Koniaris
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

View more
  28 in total

1.  Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.

Authors:  Katarzyna Kempinska; Bhavna Malik; Dmitry Borkin; Szymon Klossowski; Shirish Shukla; Hongzhi Miao; Jingya Wang; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Mol Cancer Ther       Date:  2017-11-15       Impact factor: 6.261

2.  Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice.

Authors:  Xiaoling Jin; Teresa A Zimmers; Yanlin Jiang; Daniel P Milgrom; Zongxiu Zhang; Leonidas G Koniaris
Journal:  Surgery       Date:  2018-02-01       Impact factor: 3.982

Review 3.  Growth differentiation factor 15 (GDF15) in cancer cell metastasis: from the cells to the patients.

Authors:  Anna Spanopoulou; Vasiliki Gkretsi
Journal:  Clin Exp Metastasis       Date:  2020-06-05       Impact factor: 5.150

4.  Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?

Authors:  Leonidas G Koniaris; David M Levi; Felipe E Pedroso; Dido Franceschi; Andreas G Tzakis; Juan A Santamaria-Barria; Jennifer Tang; Marissa Anderson; Subhasis Misra; Naveenraj L Solomon; Xiaoling Jin; Peter J DiPasco; Margaret M Byrne; Teresa A Zimmers
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

5.  Resveratrol Improves Recovery and Survival of Diet-Induced Obese Mice Undergoing Extended Major (80%) Hepatectomy.

Authors:  Xiaoling Jin; Teresa A Zimmers; Zongxiu Zhang; Leonidas G Koniaris
Journal:  Dig Dis Sci       Date:  2018-10-03       Impact factor: 3.199

6.  Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer.

Authors:  Teresa A Zimmers; Juan C Gutierrez; Leonidas G Koniaris
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-27       Impact factor: 4.553

7.  Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Authors:  Femke Heindryckx; Koen Mertens; Nicolas Charette; Bert Vandeghinste; Christophe Casteleyn; Christophe Van Steenkiste; Dominique Slaets; Louis Libbrecht; Steven Staelens; Peter Starkel; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cancer       Date:  2010-08-20       Impact factor: 27.401

Review 8.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

9.  Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo.

Authors:  Kyle J Thompson; Ryan Z Swan; Tracy L Walling; David A Iannitti; Iain H McKillop; David Sindram
Journal:  Surg Endosc       Date:  2013-03-07       Impact factor: 4.584

Review 10.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.